TNF and inflammatory bowel disease: As the landscape of IBD treatment options widens, the potential opportunities for using novel combinations of TNF inhibitors with agents that target different immune pathways such as ustekinumab, vedolizumab, Janus kinase inhibitors or anti-P19 antibodies increase.